Coronavirus Treatments and Preventions Under Development at Emergent BioSolutions in Pigtown

| March 18, 2020 | 0 Comments

Emergent BioSolutions Inc. announced last week that it has initiated development of two product candidates for the treatment and prevention of the coronavirus disease (COVID-19). Emergent’s two Baltimore facilities, located in Bayview and at 1111 S. Paca St. in Pigtown/Carroll-Camden Industrial Area, will participate in the manufacturing of these products.

Robert G. Kramer Sr., president and chief executive officer at Emergent BioSolutions, stated in a press release, “As a company focused on public health threats, we are committed to responding to this novel coronavirus and will use our broad capabilities and platforms to advance solutions. On the heels of our collaboration with an industry partner to develop an experimental vaccine candidate for clinical testing, we are pleased to leverage our existing infrastructure to help expedite development of our product candidates for COVID-19, founded on our decades of experience in hyperimmune manufacturing.”

About the development from the press release:

Hyperimmunes are polyclonal antibody therapeutics derived from plasma that leverage the immune response in humans or animals and can provide immediate protection from infection. COVID-HIG, manufactured from human plasma with antibodies to SARS-CoV-2, will be developed as a potential treatment for severe hospitalized patients as well as protection for at-risk individuals. In parallel, COVID-EIG, manufactured from plasma of immunized horses with antibodies to SARS-CoV-2, will be developed as a potential treatment for severe hospitalized patients.

Emergent has initiated plasma collection efforts for both human and equine platforms with a goal of manufacturing clinical material within the next four to five months in anticipation of beginning a clinical study as early as the third quarter of 2020.

“Emergent is advancing these programs based on our hyperimmune platforms and using existing infrastructure and capabilities that we deployed for our recently completed Phase 2 clinical trial for our influenza hyperimmune FLU-IGIV to treat patients hospitalized with Influenza A,” said Laura Saward, senior vice president and therapeutics business unit head at Emergent BioSolutions. “By leveraging our platform and capabilities that are already in place, Emergent is in a state of readiness to develop treatment options for COVID-19 to potentially protect healthcare workers and others on the frontline, as well as treat individuals who have fallen ill.”

Emergent is currently completing a $50-million expansion of its facility in Pigtown.

About the Author:

Founder and Publisher of SouthBmore.com, longtime resident of South Baltimore, and a graduate of Towson University. Diehard Ravens and O's fan, beach volleyball enthusiast, dog lover, and "bar food" foodie. Email me at [email protected] and follow me on Twitter at @SoBoKevin.
×